IP Library Granted Patent US 7,674,455
Granted Patent B2
US 7,674,455 · App. 11/442,504 · Granted Mar 9, 2010

Targeted retrograde gene delivery to motor neurons

Assignee: Salk Institute for Biological Studies
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,674,455
App. No.
11/442,504
Granted
Mar 9, 2010
Kind
B2
Abstract

Methods are disclosed for delivering a heterologous gene to a cell body of a neuron by contacting a muscle tissue innervated by the neuron with a viral vector comprising a heterologous gene, wherein the viral vector enters said neuron and is retrogradely moved to the cell body. Additionally, methods for expressing secreted proteins from a nerve cell body as well as methods for treating neurodegenerative disorders such as amyotrophic lateral sclerosis are described.

Claims (8)

1. A method of treating a mammal having amyotrophic lateral sclerosis, said method comprising:

transducing a motor neuron of said mammal with an insulin-like growth factor I (IGF-1) gene or a glial cell line-derived neurotrophic factor (GDNF) gene; wherein the motor neuron comprises a synaptic region and a cellular portion; and wherein transducing the motor neuron of said mammal comprises injecting a muscle that participates in respiration in said mammal with at least 1.5×10 7 infectious particles of an adeno-associated virus (AAV) vector comprising said IGF-1 gene or said GDNF gene; wherein said muscle is innervated by said motor neuron comprising a synaptic region and a cellular portion; and wherein said AAV vector enters the synaptic region of said motor neuron, is retrogradely moved to the cell body of said motor neuron, and expresses said IGF-1 gene or said GDNF gene; thereby treating amyotrophic lateral sclerosis in the mammal.

2. The method of claim 1 , wherein the AAV vector comprises the IGF-1 gene.

3. The method of claim 1 , wherein the AAV vector comprises the GDNF gene.

4. The method of claim 1 , wherein the mammal is a human.

5. The method of claim 1 , wherein the muscle that participates in respiration in the mammal is the diaphragm or an intercostal muscle.

6. The method of claim 1 , wherein at least 1×10 8 infectious particles of the AAV vector are injected.

7. The method of claim 1 , wherein at least 1×10 9 infectious particles of the AAV vector are injected.

Assignments (5)
CONFIRMATORY LICENSE Recorded Jan 17, 2014
From: SALK INSTITUTE FOR BIOLOGICAL STUDIES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 032086/0784 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2007
From: KASPAR, BRIAN K.; GAGE, FRED H.
To: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
Reel/Frame 019599/0098 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE FROM SALK INSTITUTE FOR BIOLOGICAL STUDIES TO THE JOHNS HOPKINS UNIVERSITY PREVIOUSLY RECORDED ON REEL 019572 FRAME 0268. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 20, 2007
From: ROTHSTEIN, JEFFREY D.
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 019583/0575 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2007
From: THE JOHNS HOPKINS UNIVERSITY
To: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
Reel/Frame 019572/0258 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2007
From: ROTHSTEIN, JEFFREY D.
To: SALK INSTITUTE FOR BIOLOGICAL STUDIES
Reel/Frame 019572/0268 →
Continuity (3)
Continuation 1023756700 · Sep 5, 2002
Continuation In Part 1003204700 · Dec 21, 2001
Related Publication 20070003524A1 · Jan 4, 2007